IBA, NeuroSurvival Technologies partner

Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has signed a collaboration agreement with molecular imaging and therapy developer NeuroSurvival Technologies (NST) of Petach-Tikva, Israel.

The agreement calls for radiolabeling and distribution of NST's ApoSense 18F-ML-10 molecular imaging agent for apoptosis to sites participating in multicenter clinical trials, according to IBA of Louvain-la-Neuve, Belgium.

Related Reading

IBA, Lantheus ink radiopharma deal, July 31, 2008

IBA, Wilex ink licensing pact, June 6, 2008

IBA finalizes acquisition of CIS bio, May 30, 2008

IBA opens U.K. production center, March 14, 2008

NST is cleared for ApoSense trials, July 25, 2008

Copyright © 2008 AuntMinnie.com

Page 1 of 435
Next Page